Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 5 Insulin Resistance 3 Diabetes Mellitus, Type 2 3 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Diabetes Mellitus 2 Carotid Intimal Medial Thickness 1 2 Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Pharmacokinetics of MDV3100 1 Neoplasms 1 Neoplasm Metastasis 1 Meningioma 1 Memory Disorders 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukoplakia, Oral 1 Leukemia, Myeloid, Chronic-Phase 1 Inflammation 1 Head and Neck Neoplasms 1 Glioblastoma 1 Cognitive Dysfunction 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 14 Radiotherapy 10 Ifosfamide 10 Trabectedin 7 pazopanib 4 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 temsirolimus 2 romidepsin 2 ribociclib 2 pegfilgrastim 2 eribulin 2 cixutumumab 2 brigimadlin 2 belinostat 2 Vincristine 2 Sunitinib 2 Radiotherapy, Conformal 2 Gemcitabine 2 Epirubicin 2 Dexamethasone 2 Dactinomycin 2 Carboplatin 2 soblidotin 1 sitravatinib 1 siremadlin 1 selinexor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Liposarcoma × Pioglitazone × Clear all

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡